Serum Creatinine as a Predictive Tool of Adverse Outcomes in Covid-19 Patients in Douala
Créatinine Sérique comme Outil Prédictif des Résultats Défavorables chez les Patients Atteints de Covid-19 à Douala.
DOI:
https://doi.org/10.5281/hra.v2i5.5586Keywords:
prevalence, Covid-19, Serum, Douala, creatinineAbstract
ABSTRACT
Introduction. Renal impairment is frequent in hospitalized patients with COVID-19 and is associated with poor outcomes. The aim of our study was to assess the prevalence of elevated serum creatinine in COVID-19 patients at the Douala General and Laquintinie Hospitals in Douala. Methods. This was a hospital-based retrospective cohort study from March 2020 to March 2022. We included all files of patients admitted and diagnosed of Covid-19 using the RDT, RT-PCR, chest CT Scan and/or clinical symptoms. We noted the highest serum creatinine values during admission. Elevated serum creatinine was defined as >13mg/l for males, and >12mg/l for females. Results. A total of 543 files were included. The prevalence of elevated serum creatinine was 50%. Hypertension and type 2 diabetes mellitus were significantly more prevalent in patients with elevated creatinine (p=0.001 and p=0.014) respectively. The most common biological abnormalities associated with elevated creatinine were: elevated C-reactive protein and D-dimer, neutrophilia, and lymphopenia. Patients with elevated creatinine received more oxygen therapy (p=0.046). The mortality rates were 45.8% and 14.1% in patients with elevated and normal Creatinine respectively (p<0.001). On multivariate analysis, age>60 years, and low oxygen saturation <95 % (aOR 3.116, 95% CI 1.368-7.099) were independent predictors of mortality in COVID-19 patients with kidney impairment. Conclusion. Half of hospitalized patients with COVID-19 had elevated Serum creatinine, and about one out of two of them died.
RESUME
Introduction. Les troubles rénaux sont fréquents chez les patients hospitalisés atteints de la COVID-19 et sont associés à de mauvais résultats. L'objectif de notre étude était d'évaluer la prévalence de l'élévation de la créatinine sérique chez les patients atteints de la COVID-19 à l’hôpital général de Douala et Laquintinie à Douala. Méthodes. Il s'agissait d'une étude de cohorte rétrospective basée sur des données hospitalières de mars 2020 à mars 2022. Nous avons inclus tous les dossiers des patients hospitalisés et diagnostiqués avec la Covid-19 à l'aide du test RDT, de la RT-PCR, de la tomodensitométrie thoracique et/ou des symptômes cliniques. Nous avons noté les valeurs les plus élevées de créatinine sérique lors de l'admission. Une élévation de la créatinine sérique était définie comme >13mg/l pour les hommes et >12mg/l pour les femmes. Résultats. Un total de 543 dossiers ont été inclus. La prévalence de l'élévation de la créatinine sérique était de 50 %. L'hypertension et le diabète de type 2 étaient significativement plus fréquents chez les patients présentant une créatinine élevée (p=0,001 et p=0,014) respectivement. Les anomalies biologiques les plus courantes associées à une créatinine élevée étaient : une augmentation de la protéine C-réactive et du D-dimère, une neutrophilie et une lymphopénie. Les patients avec une créatinine élevée ont reçu plus de thérapie à l'oxygène (p=0,046). Les taux de mortalité étaient de 45,8 % et 14,1 % chez les patients avec une créatinine élevée et normale respectivement (p<0,001). Dans l'analyse multivariée, l'âge>60 ans et une saturation en oxygène faible <95 % (aOR 3,116, IC à 95 % 1,368-7,099) étaient des prédicteurs indépendants de la mortalité chez les patients atteints de la COVID-19 avec des troubles rénaux. Conclusion. La moitié des patients hospitalisés atteints de la COVID-19 présentaient une élévation de la créatinine sérique, et environ sur sur deux d'entre eux est décédé.
References
Kapp ME, Fogo AB, Roufouse C, Najafian B, Radhakrishnan J, Mohan S, et al. Renal Considerations in COVID-19: Biology, Pathology, and Pathophysiology. ASAIO J. 2021 Oct;67(10):1087–96.
Nogueira SÁR, Oliveira SCS de, Carvalho AFM de, Neves JMC, Silva LSV da, Silva Junior GB da, et al. Renal changes and acute kidney injury in COVID-19: a systematic review. Rev Assoc Med Bras. 2020 Sep 21; 66:112–7.
Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med. 2020;46(7):1339–48.
Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219–27.
Raina R, Mahajan ZA, Vasistha P, Chakraborty R, Mukunda K, Tibrewal A, et al. Incidence and Outcomes of Acute Kidney Injury in COVID-19: A Systematic Review. Blood Purif. 2022;51(3):199–212.
Chan KW, Yu KY, Lee PW, Lai KN, Tang SCW. Global REnal Involvement of CORonavirus Disease 2019 (RECORD): A Systematic Review and Meta-Analysis of Incidence, Risk Factors, and Clinical Outcomes. Frontiers in Medicine. 2021;8(678200).
Silver SA, Beaubien-Souligny W, Shah PS, Harel S, Blum D, Kishibe T, et al. The Prevalence of Acute Kidney Injury in Patients Hospitalized With COVID-19 Infection: A Systematic Review and Meta-analysis. Kidney Med. 2020 Dec 9;3(1):83-98.e1
Nimkar A, Naaraayan A, Hasan A, Pant S, Durdevic M, Suarez CN, et al. Incidence and Risk Factors for Acute Kidney Injury and Its Effect on Mortality in Patients Hospitalized From COVID-19. Mayo Clin Proc Innov Qual Outcomes. 2020;4(6):687–95.
Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in Hospitalized Patients with COVID-19. J Am Soc Nephrol. 2021;32(1):151–60.
Lowe R, Ferrari M, Nasim-Mohi M, Jackson A, Beecham R, Veighey K, et al. Clinical characteristics and outcome of critically ill COVID-19 patients with acute kidney injury: a single centre cohort study. BMC Nephrol. 2021 Mar 15; 22:92.
Serum Creatinine and Renal Function | Annual Review of Medicine [Internet]. Available from:https://www.annualreviews.org/doi/abs/10.1146/annurev.me.39.020188.002341.
Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. JASN. 2020 Jun 1;31(6):1157–65.
Bjornsson TD. Use of serum creatinine concentrations to determine renal function. Clin
Pharmacokinet. 1979;4(3):200–22.
Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of
ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7.
Sloan J, Wilson J, Griffin C, Wilkie M, Chalmers J, Schembri S. Elevated creatinine is a sensitive severity marker in community-acquired pneumonia. European Respiratory Journal [Internet]. 2012 Sep 1 [cited 2022 Jun 9];40(Suppl 56). Available from: https://erj.ersjournals.com/content/40/Suppl_56/P2506.
Yang X, Jin Y, Li R, Zhang Z, Sun R, Chen D. Prevalence and impact of acute renal
impairment on COVID-19: a systematic review and meta-analysis. Crit Care. 2020; 24:356.
Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020 May;97(5):829–38.
Joseph A, Zafrani L, Mabrouki A, Azoulay E, Darmon M. Acute kidney injury in patients with SARS-CoV-2 infection. Annals of Intensive Care. 2020;10 (1):117.
Chen J, Kelley WJ, Goldstein DR. Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19. J Immunol. 2020 Jul 15;205(2):313–20.
Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020; 54:62–75.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): AReview. JAMA. 2020 Aug 25;324(8):782–93.
Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet Haematology. 2020;7(6): e438–40.
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J ThrombHaemost. 2020;18(4):844–7. Review. JAMA. 2020 Aug 25;324(8):782–93.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC BY-NC-ND 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work